Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma — TRACC  

Resectable Esophageal Cancer Clinical Trial

Official title: Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine whether the addition of the combination between cetuximab and radiotherapy to the standard chemotherapy for resectable oesophageal cancer is safe and adds efficacy.

Clinical Trial Description

This study aims at developing a novel strategy to optimize the treatment of oesophageal adenocarcinoma and gastro-oesophageal junctional tumors with curative intent. Surgery in combination with peri-operative chemotherapy, using the combination epirubicin, cisplatin and 5-FU, as defined by the recent MAGIC trial, results in 13% increase in 5-yr survival. To improve the outcome of patients with this disease we hypothesize that the addition of pre-operative combined cetuximab-radiotherapy (cetux-RT) treatment could improve the outcome of this patient category through better local control. ;

Related Conditions & MeSH terms

• Adenocarcinoma
• Esophageal Neoplasms
• Resectable Esophageal Cancer

• NCT number: NCT00827671
• Study type: Interventional
• Source: UMC Utrecht
• Status: Terminated
• Phase: Phase 2
• Start date: March 2009
• Completion date: March 2016